Clinical development failure or delay
Early-stage product candidates may not show sufficient safety or efficacy.
- Scope
- SENTI-202 and other pipeline programs
- Materiality
- high
Senti Biosciences, Inc.
Senti Biosciences, Inc. is a U.S.-based biotechnology company focused on developing gene circuit-based cell and gene therapies. Its platform is used to engineer programmable therapeutic cells and related product candidates for oncology and other serious diseases, with research and development centered in the United States.
1.67
1.31
| % | |
|---|---|
| Gene circuit platform | 70% Core synthetic biology platform used to design programmable therapeutic cells. |
| Lead product candidates | 20% Therapeutic programs such as SENTI-202 and SENTI-301A in development. |
| Research and development services | 10% Internal discovery, preclinical, clinical, and regulatory development work. |
Senti Biosciences does not currently sell commercial products; its primary counterparties are clinical investigators,...
- Clinical trial investigators and sitesprimary
They administer studies of SENTI-202 and other candidates and generate clinical data.
- Biopharma collaboration partnersprimary
They may license, co-develop, or help commercialize platform-derived programs.
- Contract manufacturers and suppliersprimary
They provide reagents, materials, and manufacturing capacity for development.
- Future healthcare providersemerging
Hospitals and treatment centers would buy approved therapies if commercialization succeeds.
Senti Biosciences is headquartered and operates primarily in the United States, where its long-lived assets are located...
- •United States is the core operating base and asset location
- •R&D and management functions are centered in the U.S.
- •China exposure comes through a partnered investigator-sponsored trial
- •International collaboration adds regulatory and execution complexity
- •No current revenue concentration disclosure was provided
Senti Biosciences is focused on advancing its gene circuit platform and moving lead programs through preclinical and...
01
Advance lead clinical programsshort-term
Clinical data are needed to validate the platform and support future approvals or partnerships.
02
Prioritize pipeline and capital allocationshort-term
Early-stage biotech companies must focus resources on the most promising programs.
03
Rely on external manufacturing and collaboratorsmedium-term
The company lacks internal commercial infrastructure and depends on third parties for execution.
The company faces the typical risks of an early-stage biotech developer: clinical failure, regulatory setbacks, and...
Manufacturing scale-up risk
Cell and gene therapies require reproducible, high-quality manufacturing at scale.
- Scope
- Exclusive reliance on GeneFab for SENTI-202 production
- Materiality
- high
Third-party dependency risk
The company relies on external parties for trials, preclinical work, and manufacturing.
- Scope
- CROs, CMOs, collaborators, suppliers
- Materiality
- high
Supply chain and reagent variability
Limited vendors and inconsistent inputs can disrupt development and affect outcomes.
- Scope
- Specialty materials, reagents, and equipment
- Materiality
- medium
International collaboration and regulatory risk
Cross-border work can be affected by local regulation, politics, and operational issues.
- Scope
- China collaboration for SN301A
- Materiality
- medium
Research and development expense classification
Drives the largest operating expense line in a development-stage biotech
Fair value measurement of related-party derivatives
Can create non-cash gains or losses in the income statement
Sublease income recognition and reversals
Can materially change other income and reported period comparability
Lease accounting
Influences operating expense presentation and cash flow timing
: 29.4.2026